- Home
- LDI vs KROS Comparison
LDI vs KROS Comparison
Compare LDI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDI | KROS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 584.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LDI | KROS |
|---|---|---|
| Price | $1.93 | $15.67 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $3.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 2.5M | 248.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.85 |
| EPS | N/A | ★ 2.68 |
| Revenue | N/A | N/A |
| Revenue This Year | $25.60 | $6,898.87 |
| Revenue Next Year | $23.83 | N/A |
| P/E Ratio | ★ N/A | $6.04 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $9.12 |
| 52 Week High | $5.05 | $22.55 |
Technical Indicators
Market Signals| Indicator | LDI | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 29.25 |
| Support Level | $1.51 | $15.12 |
| Resistance Level | $2.13 | $16.12 |
| Average True Range (ATR) | 0.11 | 0.61 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 5.56 | 8.76 |
Price Performance
Historical ComparisonAbout LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.